Journal articles: 'Ryōma'

1

Ohe, Tohru. "Results From the Kochi RYOMA Study." Circulation Journal 73, no. 9 (2009): 1589–90. http://dx.doi.org/10.1253/circj.cj-09-0433.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lee, Hwa-Hyung, and Ji-Hwan Lee. "A Study on the Japan Bushido Culture - Focusing on the Bushido of Ryoma Sakamoto Projected on Ryoma Goes -." Journal of Sport and Leisure Studies 76 (May 31, 2019): 23–34. http://dx.doi.org/10.51979/kssls.2019.05.76.23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chindina, Lyudmila A., and Ilyia N. Korobeynikov. "Preservation problems and prospects of research of the Ryolka burial ground and Ryolka culture." Vestnik Tomskogo gosudarstvennogo universiteta. Istoriya, no. 55 (October 1, 2018): 157–63. http://dx.doi.org/10.17223/19988613/55/23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Myunghee Park. "The Sakamoto Ryoma of the 21^st Century? Hashimoto Toru’s Political Entrepreneur Leadership." Discourse 201 15, no. 4 (November 2012): 205–34. http://dx.doi.org/10.17789/discou.2012.15.4.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

ITO, Thukasa. "On the Ryoya, Yuten and Seikunni." Journal of Research Society of Buddhism and Cultural Heritage, no. 9 (2000): 209–27. http://dx.doi.org/10.5845/bukkyobunka.2000.209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Cueto, Sergio. "Tres versiones de la intimidad." Saga. Revista de Letras 2, no. 4 (December 29, 2020): 26–34. http://dx.doi.org/10.35305/sa.v2i4.120.

Full text

Abstract:

A través de tres motivos y tres referencias diferentes, el retrato en una litografía de Paul Klee, la conversación en un haiku de Ryota y la música en un poema de T. S. Eliot, el trabajo se propone interrogar el estatuto de la intimidad como experiencia del sí mismo.

APA, Harvard, Vancouver, ISO, and other styles

7

Kubo, Toru, Takayoshi Hirota, Yuichi Baba, Yuri Ochi, Asa Takahashi, Naohito Yamasaki, Naohisa Hamashige, et al. "Patients’ Characteristics and Clinical Course of Hypertrophic Cardiomyopathy in a Regional Japanese Cohort ― Results From Kochi RYOMA Study ―." Circulation Journal 82, no. 3 (2018): 824–30. http://dx.doi.org/10.1253/circj.cj-17-0845.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Nanashima, Atsushi, Shigekazu Hidaka, Takashi Nonaka, Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro Miyazaki, et al. "Recruitment of Young Medical Apprentices (RYOMA) Project: A Comprehensive Surgical Education Program at a Local Academic Institute in Japan." Journal of Surgical Education 71, no. 4 (July 2014): 587–92. http://dx.doi.org/10.1016/j.jsurg.2013.12.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kubo, Toru, Yuichi Baba, Yuri Ochi, Asa Takahashi, Takayoshi Hirota, Naohito Yamasaki, Naohisa Hamashige, et al. "Sudden Cardiac Death-Relevant Events of Hypertrophic Cardiomyopathy in a Regional Japanese Cohort ― Results From the Kochi RYOMA Study ―." Circulation Reports 2, no. 8 (August 7, 2020): 433–39. http://dx.doi.org/10.1253/circrep.cr-20-0056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Miyamoto, Yuya, Toru Kubo, Yasuteru Nakashima, Yuichi Baba, Yuri Ochi, Asa Takahashi, Naohito Yamasaki, Yoshinori Doi, and Hiroaki Kitaoka. "Different Types of Heart Failure in Hypertrophic Cardiomyopathy in a Community-Based Japanese Cohort: Results From Kochi RYOMA Study." Journal of Cardiac Failure 23, no. 10 (October 2017): S71. http://dx.doi.org/10.1016/j.cardfail.2017.08.358.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Nanashima, Atsushi. "Recruitment of Young Medical Apprentices (RYOMA) Project: A Comprehensive Surgical Education Program at a Local Academic Institute in Japan." Journal of the American College of Surgeons 223, no. 4 (October 2016): e180-e181. http://dx.doi.org/10.1016/j.jamcollsurg.2016.08.458.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Wang, Wenhao, Shohei Yamaguchi, Ayako Suzuki, Naomi Wagu, Masahiro Koyama, Akihiko Takahashi, Risa Takada, Koji Miyatake, and Kozo Nakamura. "Investigation of the Distribution and Content of Acetylcholine, a Novel Functional Compound in Eggplant." Foods 10, no. 1 (January 4, 2021): 81. http://dx.doi.org/10.3390/foods10010081.

Full text

Abstract:

Eggplants are rich in acetylcholine (ACh), which can improve high blood pressure and negative psychological states. However, information on ACh content in individual parts of eggplant and the changes in ACh content during eggplant development is limited. Therefore, we investigated the ACh content in various parts of eggplant, namely, the leaf, root, bud, calyx, ovary, fruit, exocarp, mesocarp, partition, placenta, core, fruit base, fruit center, and fruit top in 26 eggplant varieties. Furthermore, the effect of heat treatment on ACh content was investigated. The ACh content significantly differed among the eggplant varieties. The difference between the varieties with the highest and lowest ACh content was 100-fold (Tosataka: 11 ± 0.61 mg/100 g fresh weight (FW) and Ryoma: 0.11 ± 0.046 mg/100 g FW, respectively). Eggplant fruit presented the highest ACh content (4.8 mg/100 g FW); it was three times higher than that in other parts combined (1.6 mg/100 g FW). The root contained the lowest ACh content among all parts. The ACh content increased with growth after flowering. The ACh content in the fruit 1.5 months after flowering was 400 times that in the ovary. ACh was uniformly distributed in eggplant flesh. Heat treatment did not cause ACh loss in eggplant. Thus, eggplant is an excellent raw material for functional foods.

APA, Harvard, Vancouver, ISO, and other styles

13

Hirota, Takayoshi, Toru Kubo, Yuichi Baba, Yuri Ochi, Asa Takahashi, Naohito Yamasaki, Naohisa Hamashige, et al. "Clinical Profile of Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohort ― Results From Kochi RYOMA Study ―." Circulation Journal 83, no. 8 (July 25, 2019): 1747–54. http://dx.doi.org/10.1253/circj.cj-19-0186.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kubo, Toru, Hiroaki Kitaoka, Makoto Okawa, Takayoshi Hirota, Kayo Hayato, Naohito Yamasaki, Yoshihisa Matsumura, Toshikazu Yabe, and Yoshinori L. Doi. "Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a community-based Japanese population: Results from Kochi RYOMA study." Journal of Cardiology 56, no. 3 (November 2010): 314–19. http://dx.doi.org/10.1016/j.jjcc.2010.07.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Sasaki, Shokaku. "Commentaries on the Ryogon and Ryoga in the Soto Sect during the Edo Period." JOURNAL OF INDIAN AND BUDDHIST STUDIES (INDOGAKU BUKKYOGAKU KENKYU) 36, no. 1 (1987): 235–40. http://dx.doi.org/10.4259/ibk.36.235.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Kitahara, Kentaro, Shogo Matsumoto, Toshiya Yamamoto, Junichi Soejima, Tetsuya Kimura, Hiromitsu Komatsu, and Kazuyuki Abe. "Parent Identification of Eight Apple Cultivars by S-RNase Analysis and Simple Sequence Repeat Markers." HortScience 40, no. 2 (April 2005): 314–17. http://dx.doi.org/10.21273/hortsci.40.2.314.

Full text

Abstract:

As the parents of the some of the apple cultivars were unknown and others were uncertain, we investigated the parent-offspring relationships of eight apple cultivars by S-RNase analysis and SSR markers. The paternal parent of `Hida' was identified as `Golden Delicious', not the previously mentioned `Orin'. It was indicated that `Ryoka No Kisetsu' and `Korin' showing identical SSR genotype are likely sports of `Fuji'. `Fuji', rather than `Toko', seemed to be a maternal parent of `Kotoku', but was not a paternal parent of `Orei', `Starking Delicious', `Nero 26', `Empire', or `Aori 3'. Previously mentioned `Mutsu', `Indo', and `Shin Indo' were excluded as paternal parents of `Hokuto'. `Tsugaru' and `Jonathan' and were identified as the respective paternal parents of three cultivars described as having unknown paternal parents, i.e., `Aika No Kaori', `Yoko', and `Tsugaru'.

APA, Harvard, Vancouver, ISO, and other styles

17

Oda, Hirotaka, and Kazuomi Ikeda. "Radiocarbon dating of kohitsugire calligraphies attributed to Fujiwara Shunzei: Akihiro-gire, Oie-gire, and Ryosa-gire." Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 268, no. 7-8 (April 2010): 1041–44. http://dx.doi.org/10.1016/j.nimb.2009.10.092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Sato, Takashi, Tomoharu Mochizuki, Ryota Katsumi, and Yuki Takahashi. "Correction to: Functionally Oriented Alignment of the Lower Extremity Reflecting the Direction of Gait for Healthy Elderly, Knee Osteoarthritis, and Total Knee Arthroplasty Subjects." Journal of Medical and Biological Engineering 41, no. 3 (February 17, 2021): 403. http://dx.doi.org/10.1007/s40846-021-00604-4.

Full text

Abstract:

The article “Functionally Oriented Alignment of the Lower Extremity Reflecting the Direction of Gait for Healthy Elderly, Knee Osteoarthritis, and Total Knee Arthroplasty Subjects”, written by Takashi Sato · Tomoharu Mochizuki. Ryota Katsumi and Yuki Takahashi, was originally published Online First without Open Access. After publication in volume 40, issue 6, page 887–898 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2021 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The original article has been corrected.

APA, Harvard, Vancouver, ISO, and other styles

19

Kim, Shiho. "ASSCC 2012 Student Design Contest Showcases Eleven from IEEE Region 10 Schools: Best Designs by Benjamin Devlin, Kailiang Chen, and Ryota Sekimoto [People]." IEEE Solid-State Circuits Magazine 5, no. 1 (2013): 82–89. http://dx.doi.org/10.1109/mssc.2012.2228413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Jin-A Kang. "Questioning Modern Korea in the midst of Chinese Merchant Network - Review of Modern Asian Market and Korea : Opening ports, Chinese merchants, Empire, by Ryota ISHIKAWA." Journal of Humanities, Seoul National University 73, no. 3 (August 2016): 327–47. http://dx.doi.org/10.17326/jhsnu.73.3.201608.327.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Martin, Paul P., and David Woodcock. "Generalized Blob Algebras and Alcove Geometry." LMS Journal of Computation and Mathematics 6 (2003): 249–96. http://dx.doi.org/10.1112/s1461157000000450.

Full text

Abstract:

AbstractA sequence of finite-dimensional quotients of affine Hecke algebras is studied. Each element of the sequence is constructed so as to have a weight space labelling scheme for Specht⁄standard modules. As in the weight space formalism of algebraic Lie theory, there is an action of an affine reflection group on this weight space that fixes the set of labelling weights. A linkage principle is proved in each case. Further, it is shown that the simplest non-trivial example may essentially be identified with the blob algebra (a physically motivated quasihereditary algebra whose representation theory is very well understood by Lie-theory-like methods). An extended role is hence proposed for Soergel's tilting algorithm, away from its algebraic Lie theory underpinning, in determining the simple content of standard modules for these algebras. This role is explicitly verified in the blob algebra case. A tensor space representation of the blob algebra is constructed, as a candidate for a full tilting module (subsequently proven to be so in a paper by Martin and Ryom-Hansen), further evidencing the extended utility of Lie-theoretic methods. Possible generalisations of this representation to other elements of the sequence are discussed.

APA, Harvard, Vancouver, ISO, and other styles

22

Kitagawa, Yoshiyuki, Shichiro Abe, Shigeru Toyoda, Shintaro Watanabe, Katsuto Ebisawa, Yoshiaki Murakami, Toshiyuki Takahashi, Hiroyuki Sugimura, Isao Taguchi, and Teruo Inoue. "Gender Differences in the Ratio of Eicosapentaenoic Acid to Arachidonic Acid in an Inland Prefecture, Tochigi: Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease (TREAT-CAD)." Internal Medicine 53, no. 3 (2014): 177–82. http://dx.doi.org/10.2169/internalmedicine.53.0618.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Abe, Shichiro, Hiroyuki Sugimura, Shintaro Watanabe, Yoshiaki Murakami, Katsuhito Ebisawa, Tatsuya Ioka, Toshiyuki Takahashi, Toshiaki Ando, Kaori Kono, and Teruo Inoue. "Eicosapantaenoic acid treatment based on the EPA/AA ratio in patients with coronary artery disease: follow-up data from the Tochigi Ryomo EPA/AA Trial in Coronary Artery Disease (TREAT-CAD) study." Hypertension Research 41, no. 11 (September 20, 2018): 939–46. http://dx.doi.org/10.1038/s41440-018-0102-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Tremblay-Boily, Guillaume. "Le cosmopolitisme : enjeux et débats contemporains,sous la dir. de Ryoa Chung et Geneviève Nootens, Montréal, Les Presses de l’Université de Montréal, 2010, 270 p." Politique et Sociétés 31, no. 2 (2012): 165. http://dx.doi.org/10.7202/1014363ar.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

KANIE, Yoshihiro. "A FUNDAMENTAL STUDY OF MOBILITIES IN THE LIFE OF INHABITANTS, WHO LIVE IN THE PREFECTURE EDGE, AND THE COOPERATIONS BETWEEN REGIONS : Part I In the case of working, studying and shopping at Ryomo region." Journal of Architecture and Planning (Transactions of AIJ) 62, no. 493 (1997): 175–83. http://dx.doi.org/10.3130/aija.62.175_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Crespo Golmar, A., C. Moriano, I. González Fernández, X. E. Larco Rojas, A. López Robles, and T. Pérez Sandoval. "SAT0622-HPR SAFETY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN BIOLOGICAL TREATMENT OVER 65 YEARS OF AGE." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1271.2–1271. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5260.

Full text

Abstract:

Background:A bias has been described with the lowest prescription of biologic treatments (bDMARD) in patients with rheumatoid arthritis (RA) in the elderly, despite presenting activity rates comparable to young population and higher risk of functional disability. This could be due to concerns about co-morbidities and polypharmacy1.Objectives:1) To define the characteristics of patients with RA ≥65 years and bDMARD to follow up in the Day Hospital of University Assistance Complex of León during the last year. 2) To record the incidence rate (IT) and ratio of incidence rates (RDI) of infections, neoplasms and cardiovascular events (CD) during the course of your therapy.Methods:Observational, retrospective study of patients diagnosed with RA according to ACR 1987 and/or ACR 2010 criteria in intravenous biological treatment during 2019 with ≥65.Results:40 patients with an average age at diagnosis of 55.9±15.76 years were included, 67.5 % of them were women. The average duration of the disease was 17.65±13.15 years. 40% had a history of smoking, 35% hypertension, 20% dyslipemia and 20% diabetes mellitus. A 97.5% were positive FRRA, 57% positive ACPA, 37.5% nodular and 65% erosive. As for pre-treatment, 70% had been with conventional (cDMARD) ≥2DMARD (Methotrexate (MTX) (92.5%) and Leflunomide (60%)). The mean dose of prednisone was 8.79 ±10.14 mg/day. The incidence rate of infections was 1.5%, and neoplasms and CD were 0.75% per person-years. The age at the beginning of the first bDMARD was 67.45 ± 8 years, the second (n=20) 67.98±6.64 and the third (n=7) 71.79±7.49. The first biological was a 52.5% anti-TNF, 5% anti-CTLA4, 30% anti-CD20 and 12.5% antiIL6 (25% monotherapy and combined with MTX 57.5%). The second was 30% anti-TNF, 25% antiCTLA4, 15% antiIL6 and 30% antiCD20 (50% in monotherapy and 40% methotrexate); with the third anti-TNF 42.85%, antiCTLA4 14.29%, antiIL6 14.29% and antiCD20 28.57% (42.86% in monotherapy and 42.46 with methotrexate). The mean doses of prednisone were 6.08±6.82, 4.38±7.21 and 6.95±5.94 mg/day respectively. The IT of bDMARD infections were 8.81%, 19.81% and 7.4% person-years; of neoplasia 1.04%, 0 and 0; and EC 3.63%, 0 and 1.85 person-years. The RTIs with first, second and third biological infections were: 5.88, 13.25, 4.95; with neoplasms 1.38; with EC 1.38, 0 and 0.69. The mean total accumulated corticosteroid dose was 17.69±15.01 mg/day.Conclusion:1) Patients over 65 years old receiving bDMARD in our Day Hospital in 2019 were long-standing RA with aggression data, who had not responded to ≥2 cDMARD and required medium-high doses of prednisone.2) In our sample there is a link between incidence of infection and the introduction of biological therapy, which is maintained with the increasing age of our patients, and it is not so clear with neoplasms and CD. These data are consistent with the existing literature1,2,3.3) Larger, comparative studies with RA under 65 years are needed, but it is reasonable to conclude that if bDMARD is required, elderly patients could be a high-risk group for infections, requiring special monitoring and follow-up.References:[1]Alla Ishchenko, Rik J. Lories. Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Olfer Rheumatoid Arthritis Patients: Staying the distance. Drugs Aging 2016;(33):387-398.[2]Atsuko Murota, Yuko Kaneko, Kunihiro Yamaoka y Tsutomu Takeuchi. Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis. J Rheumatol 2016; (43): 1984-1988.[3]Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Toru Hirano, Ryota Hara, Masaki Katayama et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis. The ANSWER cohort study. PLoS ONE 14 (15):e0216624Disclosure of Interests:None declared

APA, Harvard, Vancouver, ISO, and other styles

27

Karim, Kouzbari, Gostynska Sandra, Sonia Elhadad, Dube Pratibha, Jeffrey Laurence, and Jasimuddin Ahamed. "Differential Effects of HIV Protease Inhibitors on Release and Activation of Platelet-Derived TGF-β1: Potential Association with HIV-Linked CVD." Blood 134, Supplement_1 (November 13, 2019): 2341. http://dx.doi.org/10.1182/blood-2019-126225.

Full text

Abstract:

Combination antiretroviral therapies (cART) have markedly reduced mortality in HIV infection. However, cardiovascular disease (CVD), including heart failure linked to fibrosis, remains a major cause of morbidity and mortality in HIV/cART patients. The magnitude of this risk increases with use of certain protease inhibitors (PI), but the underlying mechanism remains unclear. We showed that the PI ritonavir leads to increased plasma levels of the pro-fibrotic cytokine TGF-β1, cardiac dysfunction, and pathologic cardiac fibrosis in wild-type (wt) C57BL/6 mice. Mice with targeted depletion of platelet TGF-β1 had reduced cardiac fibrosis and partially preserved cardiac function following ritonavir exposure (Laurence, et al. PLoS One 2017;12:e0187185). Several groups have examined the effects of a variety of cART agents on agonist-induced platelet aggregation, but correlations with clinical CVD are weak. Since platelets are a rich source of TGF-β1, we hypothesized that ritonavir and other PIs linked clinically to an increased CVD risk directly activate platelets to release TGF-β1 and activate latent (L)TGF-β1 to initiate signaling for organ fibrosis. We examined the impact of clinically relevant doses of ritonavir, alone and in combination with two other contemporary PIs, atazanavir and darunavir, which are currently used along with low dose ritonavir in so-called PI-boosted cART regimens. We incubated human platelet-rich plasma and washed platelets with PIs alone or in combinations at various doses for 10 min at 37°C in a platelet aggregometer (BioData. Corp). Total and active TGF-β1 levels were measured by ELISA. For in vivo assessment, we treated wt mice with a low dose of ritonavir, as used in PI-boosted cART, and measured the levels of plasma TGF-β1 by ELISA, and TGF-β1 signaling in tissues by immunofluorescence imaging for pSmad2. We found that ritonavir dose-dependently increased total TGF-β1 release from freshly-isolated platelet-rich plasma and washed human platelets. This release was blocked by ceefurin-1 and MK517, potent inhibitors of the ATP binding cassette transporter ABCC4. Darunavir alone did not cause release of TGF-β1, and did not alter significantly ritonavir-induced TGF-β1 release (Figure-1A). Atazanavir alone did induce release of TGF-β1 from platelets and did not affect the extent of such release induced by ritonavir (Figure-1A). Since total TGF-β1 released from platelets must be activated in order to signal, we tested whether these PIs could activate LTGF-β1. Ritonavir alone, in low dose, activated TGF-β1 by 4-5-fold (Fig-1B). Darunavir alone did not activate LTGF-β1, and had only a minor effect on ritonavir-induced TGF-β1 activation (Fig-1B). In marked contrast, while atazanavir also did not activate LTGF-β1, it significantly inhibited ritonavir-induced LTGF-β1 activation (Fig-1B). For in vivo assessment, wt mice were injected daily for 8 weeks with ritonavir, which dose-dependently increased plasma TGF-β1 levels (mean levels with vehicle 2.1 ng/ml; 6.4 ng/ml with 5 mg/kg ritonavir; 8.5 ng/ml with 10 mg/kg ritonavir). Increased TGF-β1 levels correlated with development of pathologic fibrosis and increased phosphorylated Smad signaling in hearts of ritonavir-treated vs. vehicle-treated mice. Clinical correlations with these in vitro and in vivo mouse studies are important. The fact that ritonavir effected both release and activation of platelet TGF-β1 is consistent with its ability to induce cardiac fibrosis and dysfunction in mice, and its association with accelerated CVD in HIV-infected individuals. Our findings that low dose ritonavir in combination with darunavir induced release and activation of platelet TGF-β1, whereas atazanavir blocked TGF-β1 activation, are consistent with the strong association of ritonavir-boosted darunavir, but not ritonavir-boosted atazanavir, with CVD in the setting of HIV (Ryom, et al. Lancet-HIV 2018;5:e291-e300). Future work will examine the effects of other contemporary cART agents, including cobicistat, which is currently replacing ritonavir in many PI-boosted therapies and some integrase-boosted regimens, on TGF-β1 release and activation, for which correlations with clinical CVD are not yet available. Identification of the mechanism of pathologic fibrosis in the heart, and potentially other organs affected by certain cART regimens, such as the kidney, may suggest specific therapeutic interventions. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

28

Ebina, K., T. Hirano, Y. Maeda, W. Yamamoto, M. Hashimoto, K. Murata, T. Takeuchi, et al. "OP0025 DRUG RETENTION OF 7 BIOLOGICS AND TOFACITINIB IN BIOLOGICS-NAÏVE AND BIOLOGICS-SWITCHED PATIENTS WITH RHEUMATOID ARTHRITIS -THE ANSWER COHORT STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 18.2–19. http://dx.doi.org/10.1136/annrheumdis-2020-eular.814.

Full text

Abstract:

Background:EULAR recommendation announced that biological disease-modifying antirheumatic drugs (bDMARDs) and janus kinase inhibitors (JAKi) are considered as equivalent in the treatment of rheumatoid arthritis (RA). However, we still lack reliable evidence of direct comparison between these agents’ retention, which may reflect both effectiveness and safety.Objectives:The aim of this multi-center (7 university-related hospitals), retrospective study is to clarify retention rates and reasons for discontinuation of 7 bDMARDs and tofacitinib (TOF), one of the JAKi, in both bDMARDs-naïve and bDMARDs-switched cases.Methods:This study assessed 3,897 patients and 4,415 treatment courses of with bDMARDs and TOF from 2001 to 2019 (2,737 bDMARDs-naïve patients and 1,678 bDMARDs-switched patients [59.5% switched to their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; DAS28-ESR 4.3; concomitant prednisolone [PSL] 6.1 mg/day [42.4%] and methotrexate [MTX] 8.5 mg/week [60.9%]). Treatment courses included abatacept (ABT; n=663), adalimumab (ADA; n=536), certolizumab pegol (CZP; n=226), etanercept (ETN; n=856), golimumab (GLM; n=458), infliximab (IFX; n=724), tocilizumab (TCZ; n=851), and TOF (n=101/only bDMARDs-switched cases). Reasons for discontinuation were classified into four categories by each attending physician: 1) lack of effectiveness, 2) toxic adverse events, 3) non-toxic reasons, and 4) remission. Retention rates of each discontinuation reason were estimated at 36 months using the Kaplan-Meier method and adjusted for potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX, starting date and number of switched bDMARDs) using Cox proportional hazards modeling.Results:Adjusted drug retention rates for each discontinuation reason were as follows: lack of effectiveness in the bDMARDs-naïve group (from 70.8% [CZP] to 85.1% [ABT]; P=0.001 between agents) and the bDMARDs-switched group (from 52.8% [CZP] to 78.7% [TCZ]; P<0.001 between agents). Toxic adverse events in the bDMARDs-naïve group (from 86.9% [IFX] to 96.3% [ABT]; P<0.001 between agents) and the bDMARDs-switched group (from 81.1% [ADA] to 95.4% [ETN]; P=0.01 between agents). Finally, overall retention rates excluding discontinuation for non-toxic reasons or remission ranged from 64.2% (IFX) to 82.0% (ABT) (P<0.001 between agents) in the bDMARDs-naïve group (figure a) and from 44.2% (ADA) to 66.8% (TCZ) (P<0.001 between agents) in the bDMARDs-switched group (figure b).Conclusion:Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.Disclosure of Interests:Kosuke Ebina Grant/research support from: KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan., Employee of: KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho., Speakers bureau: KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Sanofi, and UCB Japan., Toru Hirano Grant/research support from: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Speakers bureau: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Yuichi Maeda Grant/research support from: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Speakers bureau: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Wataru Yamamoto: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Tohru Takeuchi Grant/research support from: TT received a research grant from Chugai, CoverLetter and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Abbvie, Bristol-Myers Squibb, Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei, Employee of: TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, Astellas, Eisai, and Takeda), Hideyuki Shiba: None declared, Yonsu Son: None declared, Hideki Amuro: None declared, Akira Onishi Speakers bureau: AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, Kengo Akashi: None declared, Ryota Hara Speakers bureau: RH received a speaker fee from AbbVie, Masaki Katayama: None declared, Keiichi Yamamoto: None declared, Atsushi Kumanogoh Grant/research support from: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Speakers bureau: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Makoto Hirao Speakers bureau: MHirao received a speaker fee from Astellas, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Ayumi, and Takeda

APA, Harvard, Vancouver, ISO, and other styles

29

Murakami, K., M. Hashimoto, K. Murata, W. Yamamoto, R. Hara, M. Katayama, A. Onishi, et al. "THU0107 OBESITY PREDICTS RESPONSE TO NOT ALL BUT CERTAIN BIOLOGICAL / TARGETED DISEASE MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS - RESULTS FROM KANSAI CONSORTIUM FOR WELL-BEING OF RHEUMATIC DISEASE PATIENTS (ANSWER COHORT)." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 267.2–268. http://dx.doi.org/10.1136/annrheumdis-2020-eular.799.

Full text

Abstract:

Background:A number of previous reports suggested that obesity is one of the baseline factors indicates refractory to biologic disease-modifying antirheumatic drugs (bDMARDs). However, difference of the significant responses appears on obesity patients depending on each kind of drug is yet unclear. However, it is yet unclear how the significant responses on obesity patients vary on each kind of drug.Objectives:To assess whether obesity affects clinical outcome in rheumatoid arthritis (RA) treated with each molecular-targeted agent including bDMARDs and tofacitinib.Methods:In Kansai consortium for well-being of rheumatic disease patients (ANSWER) cohort, which was the real-world retrospective cohort of clinical database for rheumatic diseases, RA patients who initiated biological / targeted disease modifying anti-rheumatic drugs were included and consecutively followed. Obesity was defined as BMI over than 25, and patients were divided between obese (“Ob”) and non-obese (“non-Ob”) patients. SDAI (simplified disease activity index) was compared between non-Ob and Ob at month 0, 3, 6, 9, 12 after the indicated drugs were administered. Using logistic regression analysis, odds ratio (OR) and their corresponding 95% confidence intervals (95% CIs) were further calculated to estimate achievement rate of SDAI remission defined as lower than 3.3 by obesity and other relevant clinical parameters. Once after the drugs were discontinued by any unfavorable reason, disease activities were no more scored and the Last Observation Carried Forward (LOCF) imputation method was used for SDAI at month 3 and thereafter.Results:A total of 1936 patients met in the inclusion criteria were under the analysis. In each drug, SDAI remission rate (non-Ob, Ob, p-value by Chi-square test) at month 12 was as follows; Infliximab (IFX, n=135): 43%, 38%, NS (not significant); Etanercept (ETN, n=188): 44%, 19%, p=0.0122; Adalimumab (ADA, n=169): 50%, 56%, NS; Golimumab (GLM, n=315): 36%, 30%, NS; Certolizumab pegol (CZP, n=131): 33%, 56%, p=0.0287; Tocilizumab (TCZ, n=423): 41%, 29%, p=0.0456; Abatacept (ABT, n=144): 26%, 23%, NS; Tofacitinib (TOF, n=69): 27%, 23%, NS. In multivariate analysis to predict SDAI remission at month 12, obesity was an independent protective factor in CZP (OR: 0.29, 95% CIs: 0.10 – 0.83), but was an independent risk factor in TCZ (OR: 1.9, 95% CIs: 1.01 – 3.61) irrespective of age, sex, disease duration, SDAI at month 0 or number of previous bDMARDs. Any other drug including ETN did not show significant result between non -Ob and Ob in the multivariate analysis.Conclusion:Obese patients were more resistant to TCZ but more effective in CZP than non-obese patients.References:[1]Ann Rheum Dis. 2018;77(10):1405-1412. Joint Bone Spine. 2019;86(2):173-183.Disclosure of Interests:Kosaku Murakami Speakers bureau: AbbVie, Eisai, and Mitsubishi Tanabe Pharma., Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Wataru Yamamoto: None declared, Ryota Hara Speakers bureau: RH received a speaker fee from AbbVie, Masaki Katayama: None declared, Akira Onishi Speakers bureau: AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, Kengo Akashi: None declared, Koji Nagai: None declared, Yonsu Son: None declared, Hideki Amuro: None declared, Toru Hirano Grant/research support from: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Speakers bureau: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Kosuke Ebina Grant/research support from: KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan., Employee of: KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho., Speakers bureau: KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Sanofi, and UCB Japan., Kohei Nishitani Grant/research support from: KN belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Masao Tanaka Grant/research support from: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Taisho Pharmaceutical, and UCB Japan., Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Taisho Pharmaceutical, Takeda Pharmaceutical, and UCB Japan., Hiromu Ito: None declared, Koichiro Ohmura Grant/research support from: Astellas Pharma, AYUMI Pharmaceutical, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Sanofi, and Takeda Pharmaceutical., Speakers bureau: AbbVie, Actelion Pharmaceuticals Japan, Asahi Kasei Pharma, AYUMI Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, and Sanofi.

APA, Harvard, Vancouver, ISO, and other styles

30

Kubo, T., T. Hirota, Y. Nakashima, Y. Baba, Y. Ochi, A. Takahashi, N. Yamasaki, Y. L. Doi, and H. Kitaoka. "P2588Sudden cardiac death relevant events of hypertrophic cardiomyopathy in a community-based Japanese cohort: results from Kochi RYOMA study." European Heart Journal 39, suppl_1 (August 1, 2018). http://dx.doi.org/10.1093/eurheartj/ehy565.p2588.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kubo, T., K. Sugiura, Y. Ochi, A. Takahashi, Y. Baba, T. Hirota, N. Yamasaki, Y. L. Doi, and H. Kitaoka. "Prognostic impact of atrial fibrillation in patients with hypertrophic cardiomyopathy in a community-based Japanese cohort: results from Kochi RYOMA study." European Heart Journal 41, Supplement_2 (November 1, 2020). http://dx.doi.org/10.1093/ehjci/ehaa946.2082.

Full text

Abstract:

Abstract Background The prognostic impact of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) is not fully elucidated. Purpose The aim of this study was to examine the prevalence and prognostic impact of AF in a prospectively assembled community-based HCM patient cohort in an aged Japanese community. Methods In 2004, we established a cardiomyopathy registration network in Kochi Prefecture, Japan, consisting of 9 hospitals, and finally 293 patients with HCM were followed. Results The ages at registration and at diagnosis were 63±14 and 56±16 years, respectively, and 197 patients (67%) were men. 86 patients (29%) showed AF. During follow-up period of 6.1±3.2 years, 44 patients died. In those patients, HCM-related deaths occurred in 23 patients with an annual mortality rate of 1.3%. Regarding HCM-related adverse events including HCM-related deaths, appropriate ICD discharge, heart failure admission and hospitalization for embolic events, a total of 77 cardiovascular events in 70 patients occurred. Multivariate analysis revealed that presence of AF, left ventricular (LV) outflow obstruction, NYHA functional class III, and lower LV fractional shortening at registration were significant predictors of these adverse events. During the follow-up period, additional 31 patients (11%) developed new-onset AF. Importantly, the incidence of HCM-related adverse events was significantly higher in patients with new AF observed from its onset compared with those with AF at registration (log-rank p=0.029) (Figure 1). Conclusions In an unselected HCM registry in an aged Japanese community, presence of AF, particularly new-onset AF, was associated with unfavorable clinical outcomes. AF is not just a marker of the disease stage but an important trigger of HCM-related adverse events. Figure 1 Funding Acknowledgement Type of funding source: None

APA, Harvard, Vancouver, ISO, and other styles

32

"Retraction: Ryota Tanaka: The therapeutic potential for cerebral infarction using neural stem cells." Juntendo Medical Journal 53, no. 4 (2007): 53_E1. http://dx.doi.org/10.14789/pjmj.53.53_e1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Sosnowska, Emilia. "A Japanese Approach to Haptic/Multimodal Art Practice and Perception." Networking Knowledge: Journal of the MeCCSA Postgraduate Network 8, no. 1 (February 1, 2015). http://dx.doi.org/10.31165/nk.2015.81.360.

Full text

Abstract:

This paper reflects a fraction of research which sets out to examine the complex constructions and debates underpinning visual culture theory, and assesses its adequacy as the main theoretical framework with which to engage in contemporary interactive art. The treatment presents digital art in Japan with its roots in traditional East Asian philosophy giving the senses a prominent role in perceiving the world and enabling perfect symbiosis between humans and machines. This paper points out the expansion of this culturally and traditionally inspired spirituality from its natural and cultural context to contemporary digitally mediated environments. This is accomplished through an analysis of digital interactive work by specific artists located in Japan, such as Kumiko Kushiyama, Masaki Fujihata and Ryota Kuwakubo.

APA, Harvard, Vancouver, ISO, and other styles

34

Pronovost, Gilles. "Ryoa CHUNG et Geneviève NOOTENS (dir.) (2010), Le cosmopolitisme. Enjeux et débats contemporains." Communication, no. 34/1 (August 17, 2016). http://dx.doi.org/10.4000/communication.6855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Ryōma'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles